Literature DB >> 31913471

DPP-4 as a Novel Biomarker for Inflammatory Bowel Disease: Is It Ready for Clinical Use?

Courtney Perry1, Neeraj Kapur1, Terrence A Barrett1.   

Abstract

Entities:  

Year:  2020        PMID： 31913471      PMCID： PMC7584134          DOI： 10.1093/ibd/izz320

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  13 in total

1.  Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study.

Authors:  Khalaf Kridin; Kyle Amber; Mogher Khamaisi; Doron Comaneshter; Erez Batat; Arnon D Cohen
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

2.  Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?

Authors:  Valle García-Sánchez; Eva Iglesias-Flores; Raúl González; Javier P Gisbert; José María Gallardo-Valverde; Angel González-Galilea; Antonio Naranjo-Rodríguez; Juan F de Dios-Vega; Jordi Muntané; Federico Gómez-Camacho
Journal:  J Crohns Colitis       Date:  2009-12-02       Impact factor: 9.071

Review 3.  Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.

Authors:  Gian Paolo Fadini; Angelo Avogaro
Journal:  Vascul Pharmacol       Date:  2011-05-31       Impact factor: 5.773

Review 4.  Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection.

Authors:  Katarina Tomovic; Jelena Lazarevic; Gordana Kocic; Marina Deljanin-Ilic; Marko Anderluh; Andrija Smelcerovic
Journal:  Med Res Rev       Date:  2018-05-28       Impact factor: 12.944

Review 5.  C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.

Authors:  Mahmoud H Mosli; Guangyong Zou; Sushil K Garg; Sean G Feagan; John K MacDonald; Nilesh Chande; William J Sandborn; Brian G Feagan
Journal:  Am J Gastroenterol       Date:  2015-05-12       Impact factor: 10.864

6.  Dipeptidyl peptidase 4 (DPP4), adipose inflammation, and insulin resistance: is it time to look to the hepatocyte?

Authors:  Wellington S Silva Júnior; Maria das Graças C Souza; Luiz Guilherme Kraemer-Aguiar
Journal:  Hepatobiliary Surg Nutr       Date:  2018-12       Impact factor: 7.293

7.  Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.

Authors:  Jean-Frederic Colombel; Remo Panaccione; Peter Bossuyt; Milan Lukas; Filip Baert; Tomas Vaňásek; Ahmet Danalioglu; Gottfried Novacek; Alessandro Armuzzi; Xavier Hébuterne; Simon Travis; Silvio Danese; Walter Reinisch; William J Sandborn; Paul Rutgeerts; Daniel Hommes; Stefan Schreiber; Ezequiel Neimark; Bidan Huang; Qian Zhou; Paloma Mendez; Joel Petersson; Kori Wallace; Anne M Robinson; Roopal B Thakkar; Geert D'Haens
Journal:  Lancet       Date:  2017-10-31       Impact factor: 79.321

8.  Dipeptidyl peptidase-4 expression is reduced in Crohn's disease.

Authors:  G W Moran; C O'Neill; P Padfield; J T McLaughlin
Journal:  Regul Pept       Date:  2012-05-02

9.  Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.

Authors:  Devin Abrahami; Antonios Douros; Hui Yin; Oriana Hoi Yun Yu; Christel Renoux; Alain Bitton; Laurent Azoulay
Journal:  BMJ       Date:  2018-03-21

Review 10.  DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.

Authors:  Jianqiang Zhang; Qiuyue Chen; Jixin Zhong; Chaohong Liu; Bing Zheng; Quan Gong
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.